Targeting IL-17 and TH17 cells in chronic inflammation
The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Abstract
The key role of interleukin-17 (IL-17) and T helper 17 (T(H)17) cells in tissue inflammation, autoimmunity and host defence led to the experimental targeting of these molecules in mouse models of diseases as well as in clinical settings. Moreover, the demonstration that IL-17 and T(H)17 cells contribute to local and systemic aspects of disease pathogenesis, as well as the finding that the IL-17-T(H)17 cell pathway is regulated by IL-23, prompted the identification of inhibitors. These inhibitors include biotechnology products that target IL-23 as well as the leading member of the IL-17 family, IL-17A, and one of its receptors, IL-17 receptor A. Several clinical trials of these inhibitors are underway, and positive results have been obtained in psoriasis, rheumatoid arthritis and ankylosing spondylitis. This Review focuses on the current knowledge of the IL-17-T(H)17 cell pathway to better understand the positive as well as potential negative consequences of targeting them.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abs against IL-17/IL-17RA are in clinical trials for other autoimmune conditions [55].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [55]
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Research works printed but not linked: 1
- Baeten, D. et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 62, Abstract L3847 (2010).
Cited by
Items 501–600 of 1,000
Gege, C., Schlüter, T., & Hoffmann, T. K. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.09.053 · Cited by 34
Lavocat, F., Ndongo-Thiam, N., & Miossec, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00647 · Cited by 35
“IL-17A and IL-17F share 50% sequence homology and are involved in chronic inflammation and autoimmunity (2, 3).”
BackgroundSelf-citationInterleukin-17A antagonist attenuates radiation-induced lung injuries in mice
Wang, B.-Z., Wang, L.-P., Han, H., Cao, F.-L., Li, G.-Y., Xu, J.-L., Wang, X.-W., & Wang, L.-X. (2014) · Experimental Lung Research · doi:10.3109/01902148.2013.872210 · Cited by 33
Saviano, A., Mansour, A. A., Raucci, F., Merlino, F., Marigliano, N., Schettino, A., Wahid, M., Begum, J., Filer, A. D., Manning, J. E., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-224479 · Cited by 34
Liu, S., Wang, W., Chen, Z., Wu, P., Pu, W., Li, G., Song, J., & Zhang, J. (2024) · Advanced Science · doi:10.1002/advs.202401882 · Cited by 46
The role of interleukin-17 in intrahepatic cholestasis of pregnancy
Kırbaş, A., Biberoglu, E. H., Ersoy, A. Ö., Dikmen, A. U., Koca, C., Ozgu-Erdinc, A. S., Uygur, D., Çağlar, T., & Biberoglu, K. O. (2015) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2015.1028354 · Cited by 33
“Interleukin-17 (IL-17), also known IL-17A or CTLassociated antigen 8, is a recently discovered proinflammatory cytokine [9].”
BackgroundWu, N., Hsu, C., Sun, F., & Tsai, T. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13900 · Cited by 33
Hajialilo, M., Dolati, S., Abdolmohammadi‐Vahid, S., Ahmadi, M., Kamrani, A., Eghbal‐Fard, S., Ghassembaglou, A., Valizadeh, A., Shenas, M. H. M., Maleki, L. A., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28488 · Cited by 33
“Th17 cells are implicated in the pathogenesis of autoimmune diseases, and several inflammatory diseases such as rheumatoid arthritis (RA),(5) psoriasis, AS,(6) and inflammatory bowel disease (IBD).(7,8) The differentiation of Th17 cells requires the presence of IL‐23 produced by activated antigen‐presenting cells (APC…”
BackgroundJhun, J., Min, H. K., Ryu, J., Lee, S.-Y., Ryu, J.-G., Choi, J. W., Na, H. S., Lee, S. Y., Jung, Y., Park, S.-J., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02477-8 · Cited by 33
Rogers, K. V., Martin, S. W., Bhattacharya, I., Singh, R. S. P., & Nayak, S. (2020) · Clinical and Translational Science · doi:10.1111/cts.12849 · Cited by 34
“TNFα and IL-17 signaling lead to increased production of IL-6 through cells not currently included in the model but included as factors influencing the basal rate of IL-6 production.(23) Neutrophils can lead to cleavage of soluble IL-6R and production of IL-6, although the latter is still under debate.”
BackgroundKang, M., Lee, S., Park, Y. M., Kim, B. S., Lee, M.-J., Kim, J., Jeong, S., Lee, S., Park, M. J., Rhee, E. S., et al. (2021) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2021.13.3.404 · Cited by 33
Knecht, R. S., Bucher, C. H., Linthout, S. V., Tschöpe, C., Schmidt‐Bleek, K., & Duda, G. N. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.614508 · Cited by 38
“A function of IL-17 is to stimulate the expression of RANKL on osteoblasts, thereby increasing osteoclastogenesis and osteoclast activity, which may eventually lead to bone erosion (Miossec and Kolls, 2012).”
BackgroundNew insights of Nb2O5-based coatings on the 316L SS surfaces: enhanced biological responses
Moreto, J. A., Gelamo, R. V., da Silva, M. V., Steffen, T. T., Oliveira, C. J. F., Buranello, P. A. D. A., & Pinto, M. R. (2021) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-021-06498-7 · Cited by 34
“In a similar way, IL-17 is a huge pro-inflammatory cytokine associated with chronic inflammation [22], osteoclastogenesis [22] and that can amplify inflammatory responses by inducing TNF-α secretion by macrophages [23].”
BackgroundLiu, X., Wu, W., Fang, L., Liu, Y., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922782 · Cited by 37
Girardi, D., Falco, A., CARLO, A. D., Benevene, P., Comar, M., Tongiorgi, E., & Bartolucci, G. B. (2015) · Journal of Behavioral Medicine · doi:10.1007/s10865-015-9658-x · Cited by 34
“Finally, IL-17 activity contributes to both acute and chronic inflammation (Miossec & Kolls, 2012).”
BackgroundIL-17A–Producing γδ T Cells Suppress Early Control of Parasite Growth by Monocytes in the Liver
Sheel, M., Beattie, L., Frame, T. C. M., Rivera, F. D. L., Faleiro, R. J., Bunn, P. T., de, M. M., Edwards, C. L., Ng, S. S., Kumar, R., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501046 · Cited by 35
“There is now considerable evidence to support a role for IL-17 as a proinflammatory cytokine that plays a significant role in infectious diseases and autoimmunity (43, 44).”
BackgroundMa, H., Xu, J., Liu, X., Zhu, Y., Gao, B., Karin, M., Tsukamoto, H., Jeste, D. V., Grant, I., Roberts, A. J., et al. (2016) · Current Pathobiology Reports · doi:10.1007/s40139-016-0097-3 · Cited by 34
Robert, R., Ang, C., Sun, G., Juglair, L., Lim, E. X., Mason, L. J., Payne, N. L., Bernard, C. C. A., & Mackay, C. R. (2017) · JCI Insight · doi:10.1172/jci.insight.94821 · Cited by 33
“Blocking antibodies that interfere with the IL-23/IL-17 axis are an excellent example of this new knowledge translating to breakthrough medicines (4).”
BackgroundNeuwirth, T., Malzl, D., Knapp, K., Tsokkou, P., Kleißl, L., Gabriel, A., Reininger, B., Freystätter, C., Marella, N., Kutschat, A. P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.011 · Cited by 36
Yang, P., Zhang, M., Wang, X., Xu, A.-L., Shen, M., Jiang, B., Zhou, X., & Zhou, L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113822 · Cited by 34
Novel archetype in psoriasis management bridging molecular dynamics in exploring novel therapies
Yadav, K., Singh, D., & Singh, M. R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174254 · Cited by 35
Interleukin-17 Cytokines and Receptors: Potential Amplifiers of Tendon Inflammation
Mimpen, J. Y., Snelling, S. J. B., Carr, A. J., & Dakin, S. G. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.795830 · Cited by 34
“…qualities of these cytokines have made them important in the pathology of several chronic autoimmune and fibrotic inflammatory diseases (Miossec and Kolls, 2012), including psoriatic arthritis and ankylosing spondylitis, in which antibodies against IL-17A have revolutionised disease treatment…”
BackgroundChen, L., Liu, X., Wang, X., Lu, Z., & Ye, Y. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s401293 · Cited by 33
Targeting Th17 cells: a promising strategy to treat oral mucosal inflammatory diseases
Wang, Y., Xue, N., Wang, Z., Zeng, X. Y., Ji, N., & Chen, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1236856 · Cited by 36
Yamaki, S., Ine, S., Kawabe, T., Okuyama, Y., Suzuki, N., Soroosh, P., Mousavi, S. F., Nagashima, H., Sun, S., So, T., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201444701 · Cited by 33
Moran, E. M., & Mastaglia, F. L. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.06.432 · Cited by 35
“IL-17 and IL-17F share a high degree of homology and both bind to the same receptor implying common biological activities.”
InfluentialIL-2 Shapes the Survival and Plasticity of IL-17–Producing γδ T Cells
Corpuz, T. M., Vazquez-Lombardi, R., Luong, J. K., Warren, J. A., Stolp, J., Christ, D., King, C., Brink, R. A., Sprent, J., & Webster, K. E. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700335 · Cited by 33
“It is also implicated in a number of autoimmune and inflammatory pathologies where it is considered a potential target for clinical intervention (3).”
BackgroundShimada, K., Porritt, R. A., Markman, J. L., O’Rourke, J. G., Wakita, D., Rivas, M. N., Ogawa, C., Kozhaya, L., Martins, G. A., Unutmaz, D., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.08.022 · Cited by 33
“In addition to CD4 T cells, other IL-17A-producing cell populations exist; gd T cells, CD3 iNK cells, lymphoid-tissue inducer (LTi)-like cells, and NK cells are important innate IL-17A-producing cells during autoimmune inflammation and infectious diseases (Miossec and Kolls, 2012).”
Choi, B. J., Park, M. H., Jin, H. K., & Bae, J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01176-4 · Cited by 37
Neuroimmune interactions: The bridge between inflammatory bowel disease and the gut microbiota
Zhai, J., Li, Y., Liu, J., & Dai, C. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70329 · Cited by 32
“60 In mouse models colonised with microbiota from IBD patients, Th17 cells are elevated.”
IL-17 in the Rheumatologist’s Line of Sight
Truchetet, M., Mossalayi, M. D., & Boniface, K. (2013) · BioMed Research International · doi:10.1155/2013/295132 · Cited by 32
“For example, Roche is testing a blocking antibody targeting both IL-17A and IL-17F (RG7624, no clinical information available; Roche website and [36]).”
BackgroundResultInfluentialWang, H., Du, L., Liu, F., Wei, Z., Gao, L., & Feng, W.-H. (2019) · Journal of Virology · doi:10.1128/jvi.01100-19 · Cited by 32
“IL-17 binds to the heterodimeric IL-17RA/C receptor to activate many common signaling pathways, including NF- B, mitogenactivated protein kinases (MAPKs), and C/EBPs, to induce the expression of inflammatory cytokines, chemokines and granulocyte colony-stimulating factor (10, 13).”
BackgroundLin, S., Zhou, Z., Xu, C., Zeng, F., Shi, Z., Sun, J., Mei, X., Liu, C., & Li, D. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c22831 · Cited by 33
Zhang, H., Yuan, Z., Zhu, Y. J., Yuan, Z., Wang, J., Nong, C., Zhou, S., Tang, Q., Zhang, L., Jiang, Z., et al. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115422 · Cited by 33
Liver X receptors in immune cell function in humans
Waddington, K. E., Jury, E. C., & Pineda‐Torra, I. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150112 · Cited by 31
Rhinovirus inhibits IL-17A and the downstream immune responses in allergic asthma
Graser, A., Ekici, A. B., Sopel, N., Melichar, V. O., Zimmermann, T., Papadopoulos, N. G., Τaka, S., Ferrazzi, F., Vuorinen, T., & Finotto, S. (2016) · Mucosal Immunology · doi:10.1038/mi.2015.130 · Cited by 36
“Given that there is an ongoing clinical trial to block IL-17A in asthma, the role of this cytokine in the context of RV infection needs to be clarified.(22,23)”
BackgroundUnmet Needs in Axial Spondyloarthritis
Lubrano, E., Socio, A. D., & Perrotta, F. M. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8637-0 · Cited by 31
The Dysregulated IL-23/TH17 Axis in Endometriosis Pathophysiology
Sisnett, D. J., Zutautas, K. B., Miller, J. E., Lingegowda, H., Ahn, S. H., McCallion, A., Bougie, O., Lessey, B. A., & Tayade, C. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400018 · Cited by 32
Zoheir, K. M. A., Ali, N. I., Ashour, A. E., Kishta, M. S., Othman, S. I., Rudayni, H. A., Rashad, A. A., & Allam, A. A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01559-y · Cited by 31
Interventions in cytokine signaling: novel horizons for psoriasis treatment
Li, L., Liu, J., Lu, J., Wu, J., Zhang, X., Ma, T., Wu, X., Zhu, Q., Chen, Z., & Tai, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573905 · Cited by 39
“…with psoriasis, a signi fi cant elevation in the number of Th17 cells is observed within the skin tissue, and the in fl ammatory cytokines they secrete can induce the growth and proliferation of KCs, leading to the hyperplasia of the skin ’ s keratin layer and the formation of scaly lesions (65, 66).”
Mardegan, G. P., Shibli, J. A., Roth, L. A., Faveri, M., Giro, G., & Bastos, M. F. (2016) · Clinical Oral Implants Research · doi:10.1111/clr.12846 · Cited by 30
“IL-23 is essential to the maintenance and expansion of Th17 cells and plays a critical role in driving the initial inflammatory immune response against pathogens by inducing IL-17 production and recruiting neutrophils (Miossec & Kolls 2012).”
BackgroundGao, L., Zhao, Y., Wang, P., Zhang, L., Zhang, C., Chen, Q., & Zhao, C. (2017) · PubMed Central · doi:10.22038/ijbms.2017.8359 · Cited by 37
Shen, F., Verma, A. H., Volk, A. L., Jones, B. H., Coleman, B. M., Loza, M. J., Malaviya, R., Moore, B. A., Weinstock, D., Elloso, M. M., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801436 · Cited by 33
“IL-17A (secukinumab, ixekizumab) or IL-17RA (brodalumab) were approved for treatment of moderate-severe plaque psoriasis (3, 7).”
BackgroundKidzeru, E. B., Lebeko, M., Sharma, J. R., Lucia, N., Adeola, H. A., Ndlovu, H., Khumalo, N. P., & Bayat, A. (2023) · Experimental Dermatology · doi:10.1111/exd.14734 · Cited by 30
Dougados, M., Lucas, J., Desfleurs, E., Claudepierre, P., Goupille, P., Ruyssen‐Witrand, A., Saraux, A., Tournadre, A., Wendling, D., & Lukas, C. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002802 · Cited by 30
Schinner, J., Cunha, T., Mayer, J. U., Hörster, S., Kind, P., Didona, D., Keber, C. U., Hertl, M., Worzfeld, T., & Juratli, H. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203776 · Cited by 30
“Frontiers in Immunology 08 function thereby promoting the pathology of several skin diseases and chronic inflammatory immune responses (22, 38).”
BackgroundNatoli, V., Charras, A., Hofmann, S. R., Northey, S. J., Ruß, S., Schulze, F., McCann, L. J., Abraham, S., & Hedrich, C. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1245876 · Cited by 33
IFN-γ: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies
Thuner, J., & Coutant, F. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103420 · Cited by 32
Brodalumab for the treatment of psoriasis
Galluzzo, M., D’Adamio, S., Bianchi, L., & Talamonti, M. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1246957 · Cited by 32
Zayoud, M., Marcu‐Malina, V., Vax, E., Jacob‐Hirsch, J., Elad‐Sfadia, G., Barshack, I., Kloog, Y., & Goldstein, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00799 · Cited by 30
“As extensive research in murine arthritis models strongly indicates a central role for the Th17-type cells (55, 56), we focused on the effects of FTS on the induction of the Th17 response.”
BackgroundAdvances in understanding the pathophysiology of spondyloarthritis
Lories, R. J. U. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.12.001 · Cited by 35
Effect of IL-21 on the Balance of Th17 Cells/Treg Cells in the Pathogenesis of Graves’ Disease
Tan, Y. Q., Chen, W., Liu, C., Zheng, X., Guo, A., & Long, J. (2019) · Endocrine Research · doi:10.1080/07435800.2019.1600535 · Cited by 30
“Upon binding to its receptor, IL-21 can trigger a series of biological effects through activation of the JAKSTAT signaling pathway.(40) IL-21 plays a pivotal role in the process of many autoimmune diseases.”
BackgroundIdentification of tertiary sulfonamides as RORc inverse agonists
Fauber, B. P., René, O., Burton, B., Everett, C., Gobbi, A., Hawkins, J., Johnson, A. R., Liimatta, M. B., Lockey, P. M., Norman, M., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.038 · Cited by 29
Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases
Yan, J.-W., Wang, Y., Peng, W., Tao, J., Wan, Y.-N., Li, B., Mei, B., Chen, B., Yao, H. C., Yang, G., et al. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.843669 · Cited by 30
“In another way, the combination of IL-17 ligands and TNF often resulted in synergistic actions, which can be explained in part by the overlap between TNF-a and IL-17-regulated genes, and the synergistic actions of IL-17 and TNF pathway increased mRNA stability [6,20].”
BackgroundInfluentialCalpains Released by T Lymphocytes Cleave TLR2 To Control IL-17 Expression
Perez, J., Dansou, B., Hervé, R., Levi, C., Tamouza, H., Vandermeersch, S., Demey, E., Haymann, J., Zafrani, L., Klatzmann, D., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1500749 · Cited by 31
“Among these mediators, IL-17 is predominantly involved in the induction and progression of rheumatoid arthritis (34).”
BackgroundNasonov, E. L., Mazurov, V. I., Usacheva, Y. V., Chernyaeva, E. V., Ustyugov, Y. Y., Ulitin, A. B., & Ivanov, R. A. (2017) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2017-201-210 · Cited by 29
The role of metabolism in Th17 cell differentiation and autoimmune diseases
Wang, G., Su, Z., Li, H. J., Xiao, L., Li, C., & Lian, G. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108450 · Cited by 30
Azadeh, H., Alizadeh‐Navaei, R., Rezaiemanesh, A., & Rajabinejad, M. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-00933-z · Cited by 31
The Role of Podoplanin in the Immune System and Inflammation
Zhang, Z., Zhang, N., Yu, J., Xu, W., Gao, J., Lv, X., & Wen, Z. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s366620 · Cited by 30
“Commonly, an association is made between Th17 cells and the secretion of IL-17, which is a pro-inflammatory cytokine involved in several chronic inflammatory diseases.(66,67) A recent study indicates that interaction among activated lymphocytes and RA synoviocytes is critical for a high IL-17 secretion depending on th…”
BackgroundSex Steroids Effects on Asthma: A Network Perspective of Immune and Airway Cells
Borkar, N. A., Combs, C. K., & Sathish, V. (2022) · Cells · doi:10.3390/cells11142238 · Cited by 34
A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?
Kocivnik, N., & Velnar, T. (2022) · Life · doi:10.3390/life12111918 · Cited by 29
Wang, Z., Yin, L., Xiong, Z., Huang, F., Yang, N., Jiang, F., Li, H., Cui, Y., Ren, J., Cheng, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01028 · Cited by 29
Najafi, N. N., Armide, N., Akbari, A., Rahimi, V. B., & Askari, V. R. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106152 · Cited by 35
Asthma Phenotypes and Biomarkers
Grunwell, J. R., & Fitzpatrick, A. M. (2025) · Respiratory Care · doi:10.1089/respcare.12352 · Cited by 31
“In addition to in fl ammasome activation, IL-17A also promotes airway neutrophilia via chemokine ligand chemo-kines and colony-stimulating factor 3 148,149 and has been shown to mediate airway hyper-responsiveness 150 and corticosteroid resistance.”
Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis
Weitz, J. E., & Ritchlin, C. T. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.890587 · Cited by 28
“While monoclonal antibodies, like UST, target formation of Th17 cells, alternate targets for the pro-inflammatory cytokine include IL17A, IL17A-F, IL17F, as well as the IL-17 receptor (IL-17RA and IL-17RC) [34,35].”
BackgroundLee, J. W., Wu, Q., Jang, Y. P., & Choung, S. (2018) · Phytotherapy Research · doi:10.1002/ptr.6061 · Cited by 28
“IL‐17A is known to be an essential factor in host defense against pathogens and a therapeutic target of psoriasis (Miossec & Kolls, 2012).”
BackgroundLong, Y., Li, S., Qin, J., Xie, L., Gan, L., Jie, F., Wu, Y., Li, Y., & Du, Q. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.011 · Cited by 28
Interleukin-17 and matrix metalloprotease-9 expression in the mycetoma granuloma
Siddig, E. E., Edris, A. M. M., Bakhiet, S. M., van de Sande, W. W. J., & Fahal, A. H. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007351 · Cited by 28
Culibrk, R. A., & Hahn, M. S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.583884 · Cited by 32
“The pathological macrophage secretome is likewise implicated in the dysregulation of adaptive immune processes: IL-23 stimulates the activation and proliferation of Th17 cells, putative regulators of autoimmunity in RA (Miossec and Kolls, 2012).”
BackgroundLoss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension
Heukels, P., Corneth, O. B. J., van Uden, D., van Hulst, J. A. C., van den Toorn, L. M., van den Bosch, A. E., Wijsenbeek, M. S., Boomars, K. A., Kool, M., & Hendriks, R. W. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-215460 · Cited by 30
Multifunctionality of Calebin A in inflammation, chronic diseases and cancer
Brockmueller, A., Mueller, A., Kunnumakkara, A. B., Aggarwal, B. B., & Shakibaei, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962066 · Cited by 29
Tripterygium wilfordii Hook. F. and Its Extracts for Psoriasis: Efficacy and Mechanism
Wang, Y., Tian, Z., Huang, S., & Dang, N. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s439534 · Cited by 28
Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161
Bai, A., & Robson, S. C. (2015) · Purinergic Signalling · doi:10.1007/s11302-015-9457-4 · Cited by 28
“Among those Th cells, Th17 cells are critical for host protective defense and also contribute to autoimmune responses and related disorders [1].”
Tanaka, S., Toki, T., Akimoto, T., & Morishita, K. (2013) · Microbiology and Immunology · doi:10.1111/1348-0421.12052 · Cited by 30
“It is well known that Th17 cells produce IL‐17A, which is involved in human RA and arthritis in animal models (32).”
BackgroundCarrión, M., Pérez‐García, S., Jimeno, R., Juarranz, Y., González‐Álvaro, I., Pablos, J. L., Gutiérrez‐Cañas, I., & Gomariz, R. P. (2013) · NeuroImmunoModulation · doi:10.1159/000350892 · Cited by 31
Dynamic control of Th2 cell responses by STAT3 during allergic lung inflammation in mice
Lim, H., Cho, M., Choi, G., Na, H., & Chung, Y. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.03.051 · Cited by 28
Coenzyme Q10 Inhibits Th17 and STAT3 Signaling Pathways to Ameliorate Colitis in Mice
Lee, S.-Y., Lee, S., Yang, E., Kim, J. K., Kim, E., Jung, K., Jung, H., Lee, K., Lee, H. H., Lee, B., et al. (2017) · Journal of Medicinal Food · doi:10.1089/jmf.2016.3859 · Cited by 30
Immune cells in skin inflammation, wound healing, and skin cancer
Zhang, Y., & Lu, Q. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad107 · Cited by 33
The effect of exercise on depression and gut microbiota: Possible mechanisms
Yao, M., Qu, Y., Zheng, Y., & Guo, H. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111130 · Cited by 29
“Th17 cells are crucial for host protection and inflammatory responses (Miossec and Kolls, 2012), with their differentiation influenced by specific microorganisms as SFB, which induce non-inflammatory Th17 cells, while Cit-robacter -derived Th17 cells produce inflammatory factors (Omenetti et al.,…”
The Role of IL-17 in Systemic Autoinflammatory Diseases: Mechanisms and Therapeutic Perspectives
Zhang, J., & Shen, M. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09042-5 · Cited by 28
“Inhibition of IL-17 can lead to neutrophilia or functional defects in controlling infections, especially those linked to extracellular bacteria [163].”
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
“In contrast, Th17 cells are distinguished by the secretion of pro-inflammatory cytokines, such as IL-17 and IL-21, which are of great significance in initiating inflammatory responses and combating specific pathogens [144].”
Secukinumab (AIN457) in the treatment of ankylosing spondylitis
Braun, J., Baraliakos, X., & Kiltz, U. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1167183 · Cited by 29
“Adapted from Miossec & Kolls 2012.[45] Interleukin-17 (IL-17) acts on various cellular targets, leading to cell activation, release of further cytokines and chemokines, and initiation of a number of pathological processes implicated in ankylosing spondylitis.”
BackgroundPatil, P. D., Burotto, M., & Velcheti, V. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1440209 · Cited by 28
“IL-17 mediates its action through the TH17 pathway, which is regulated by CTLA-4 [41].”
BackgroundSun, N., Ma, X., Zhou, K., Zhu, C. Y., Cao, Z., Wang, Y., Xu, J., & Fu, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111984 · Cited by 27
Patra, M. C., Achek, A., Kim, G., Panneerselvam, S., Shin, H., Baek, W.-Y., Lee, W., Sung, J., Jeong, U., Cho, E.-Y., et al. (2020) · Cells · doi:10.3390/cells9071648 · Cited by 29
“The inhibition of IL-17 in the kidney and spleen was quite intriguing, as this cytokine is extensively expressed in the lungs, kidneys, liver, and spleen and has been associated with the activation and proliferation of B/T lymphocytes [63].”
BackgroundDecreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves’ Disease
Chen, Z., Liu, Y., Hu, S., Zhang, M., Shi, B., & Wang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.632492 · Cited by 29
“Given that the primary effector molecular of Th17 cells, IL-17, is associated with inflammation and chemoattraction, we speculate that the robust inflammation and chemotaxis in pGD was mediated by Th17 cells (37).”
BackgroundHe, R.-R., Wu, S., Gao, R., Chen, J., Peng, Q., Hu, H., Zhu, L., Du, Y., Sun, W., Ma, X., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001223 · Cited by 29
The Role and Involvement of Stem Cells in Periodontology
Goriuc, A., Foia, L. G., Cojocaru, K.-A., Diaconu-Popa, D. A., Sandu, D., & Luchian, I. A. (2023) · Biomedicines · doi:10.3390/biomedicines11020387 · Cited by 29
“Th17 cells with a role in osteoclastogenesis secrete chemokines such as Chemokine receptor (CCR) 2, CCR 6, and CCR 20 [24,25].”
BackgroundCurcumin as a regulator of Th17 cells: Unveiling the mechanisms
Ghoushi, E., Poudineh, M., Parsamanesh, N., Jamialahmadi, T., & Sahebkar, A. (2024) · Food Chemistry Molecular Sciences · doi:10.1016/j.fochms.2024.100198 · Cited by 39
“On the other hand, regulatory T (Treg) cells are a subset of T cells that suppress immune responses to self-antigens and prevent autoimmune reactions (Miossec and Kolls, 2012; Haftcheshmeh et al., 2022).”
BackgroundInfluentialJones, G. W., Greenhill, C., Williams, J. O., Nowell, M. A., Williams, A. S., Jenkins, B. J., & Jones, S. A. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203771 · Cited by 27
Таширева, Л. А., Михайлович, П. В., Манских, В. Н., Denisov, E. V., Savelieva, O. E., Кайгородова, Е. В., & Zavyalova, M. V. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917050029 · Cited by 31
“In the human body, Th17 lymphocytes are differentiated from the na ve CD4 T cells under the influence of TGF β and IL 6 and for a long time exist in the presence of IL 21 and IL 23 [107].”
BackgroundCoutant, F. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2019.01.005 · Cited by 27
IL-17 inhibition in axial spondyloarthritis: current and future perspectives
Torğutalp, M., & Poddubnyy, D. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1605352 · Cited by 27
“inflammatory disorders including axSpA [11,12].”
Nagashio, Y., Matsuura, Y., Miyamoto, J., Kometani, T., Suzuki, T., & Tanabe, S. (2013) · Journal of Functional Foods · doi:10.1016/j.jff.2013.07.005 · Cited by 27
Brito, J. D. S., Ferreira, G. R. S., Klimczak, E., Gryshuk, L., Santos, N. D. D. L., Patriota, L. L. D. S., Moreira, L. R., Soares, A. K. D. A., Barboza, B. R., Paiva, P. M. G., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.026 · Cited by 29
“It plays an important role in conferring immunity against extracellular pathogens [56,57], has been associated with inflammatory and autoimmune diseases [58], and is involved with the recruitment, activation, and migration of neutrophils [59].”
BackgroundChen, M., Qiao, Y., Yu, L., Wang, W., Wang, W., Sun, H., Xu, Y., Bai, J., Zhou, J., & Geng, D. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.09.017 · Cited by 52
“For example, the IL-17 signalling pathway is associated with inflammation, autoimmune diseases and host defence, and IL-17 is a pro-inflammatory cytokine that mediates the pathogenesis of multiple inflammatory diseases and augments the pro-inflammatory phenotype of macrophages [62 – 64].”
BackgroundIdentification of novel quinazolinedione derivatives as RORγt inverse agonist
Fukase, Y., Sato, A., Tomata, Y., Ochida, A., Kono, M., Yonemori, K., Koga, K., Okui, T., Yamasaki, M., Fujitani, Y., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.12.039 · Cited by 28
Crosby, D. A., Glover, L. E., Brennan, E. P., Kelly, P., Cormican, P., Moran, B., Giangrazi, F., Downey, P., Mooney, E. E., Loftus, B., et al. (2020) · Human Reproduction · doi:10.1093/humrep/deaa111 · Cited by 28
Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
Menter, A., Bhutani, T., Ehst, B. D., Elewski, B. E., & Jacobson, A. A. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00746-6 · Cited by 26
“In contrast, brodalumab blocks the IL-17 receptor A subunit, thereby inhibiting the signaling of IL-17 family cytokines, including those involved in psoriasis (e.g., IL-17A, IL17C, IL-17E, IL-17F, and IL-17A/F) [22, 23, 25, 26].”
BackgroundInfluentialLiu, H., Nie, H., Lai, W., Shi, Y., Liu, X., Li, K., Tian, L., Xi, Z., & Lin, B. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.114200 · Cited by 26
Metadata
- Authors
- Miossec, P., & Kolls, J. K.
- Affiliations
- Lyon 1 Université (FR)
- University of Pittsburgh (US)
- Corresponding author
- Miossec, Pierre
- Kolls, Jay K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-10
- Volume
- 11
- Issue
- 10
- Pages
- 763-776
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2022917731
- Cited by
- 1,414
- References
- 169
- Citations by year
- 2026: 74 · 2025: 104 · 2024: 137 · 2023: 101 · 2022: 121 · 2021: 129 · 2020: 97 · 2019: 91 · 2018: 67 · 2017: 114 · 2016: 100 · 2015: 109 · 2014: 97 · 2013: 72 · 2012: 1
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Universitaire de France
- Institut Mérieux
- National Heart, Lung, and Blood Institute (R37HL079142)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- IL-17, Th17 cells, IL-17 inhibitors, IL-23, IL-17 receptor A, psoriasis, rheumatoid arthritis, ankylosing spondylitis, chronic inflammation, autoimmunity, biologic therapy, IL-17A
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Drug Delivery Systems, Interleukin-17, Receptors, Interleukin-17, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.